title: Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Martina
authors.initials: M
authors.lastname: Canestaro
authors.forename: Eugenio
authors.initials: E
authors.lastname: Ciancia
authors.forename: Rita
authors.initials: R
authors.lastname: Fazzi
authors.forename: Roberto
authors.initials: R
authors.lastname: Marasca
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D001897:Boronic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000069286:Bortezomib; D003114:Colony-Forming Units Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000503:physiopathology; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D046509:Tissue Culture Techniques
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib